Cadrenal Therapeutics announced that late-breaking clinical data on its first-in-class 12-lipoxygenase inhibitor, CAD-1005, has been accepted for an oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH). The presentation highlights the clinical value potential of CAD-1005 for treating Heparin-Induced Thrombocytopenia (HIT), a life-threatening blood-clotting disorder triggered by an immune reaction to heparin, the most widely used blood thinner in hospitals.

The abstract, titled "12-lipoxygenase inhibition with VLX-1005 in heparin-induced thrombocytopenia," was selected by expert peer reviewers for inclusion in the session on clinical trials and breakthrough innovations. This marks the first-ever randomized, blinded, placebo-controlled trial in HIT, positioning the therapy as a Phase-3 ready candidate.

Key Details of the Presentation

Market Potential

The therapy addresses a significant unmet need in the HIT market, which carries a peak annual revenue potential of $2 billion. Cadrenal Therapeutics is advancing CAD-1005 as a late-stage novel therapy for life-threatening immune and thrombotic conditions.

Cadrenal Therapeutics, Inc. plans to submit a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration (FDA) for tecarfarin as a treatment for pediatric patients with Kawasaki disease (KD) who develop coronary artery aneurysms (CAAs) and require chronic oral anticoagulation. The company aims to present its Phase 3-ready pipeline and pediatric rare-disease expansion strategy to global pharmaceutical partners at the 2026 BIO International Convention in San Diego. If the designation is granted and tecarfarin is approved for this indication, Cadrenal would be eligible to receive a Priority Review Voucher, with recent open-market valuations ranging from $180 million to $205 million.

Kawasaki disease is the leading cause of acquired heart disease in children in developed nations. Up to 25% of untreated children with KD develop enlarged coronary arteries or CAAs. Patients with large CAAs are at risk for forming blood clots, with a continuing lifelong risk for subsequent heart attacks and sudden cardiac death, and require chronic, precise anticoagulation therapy to reduce their higher risk of clot formation.

Tecarfarin is a novel, next-generation Vitamin K antagonist (VKA) designed to overcome limitations of warfarin metabolism and potentially provide more reliable and consistent anticoagulation. "Children with large or giant aneurysms due to KD represent an important underserved orphan population," said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. "The current standard of care – warfarin - is notoriously unstable in children because of dietary variations, concurrent medications, and genetic differences in liver metabolism. Tecarfarin is metabolized in a completely different way than warfarin, and is being developed to offer a highly stable, predictable alternative."

The FDA's RPDD program targets serious or life-threatening diseases that primarily affect fewer than 200,000 people in the United States from birth through age 18. The transferable Priority Review Vouchers can be used to accelerate the FDA review of a future drug or sold to another pharmaceutical manufacturer. Congress has extended the pediatric PRV program through September 30, 2029.

At the BIO International Convention, Cadrenal will present a dual-track portfolio strategy. The Global Pharma Track focuses on CAD-1005, a first-in-class 12-LOX inhibitor that is Phase 3-ready for Heparin-Induced Thrombocytopenia (HIT) and advancing into a Phase 2a trial for Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI). The Regional & Rare Disease Track focuses on tecarfarin for Kawasaki disease, offering strong geographic synergy for Japanese and East Asian pharmaceutical companies where the incidence of the disease is historically 10 to 15 times higher than in Western nations.